Tonix's rare disease portfolio includes TNX-2900 2 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix's infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-801 3, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix's lead vaccine candidates for COVID-19 are TNX-1840 and TNX-1850 4, which are live virus vaccines based on Tonix's recombinant pox vaccine (RPV) platform. TNX-3500 5 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition.